The National Institutes of Health managed to update some of these regulations in 1994, but loopholes are regularly exploited: as of 2000, one in five NIH clinical drug trials still wasn’t using any female subjects, and of the studies that did, nearly two-thirds didn’t bother analyzing their data for sex differences.
